Crysvita for Tumor-induced osteomalacia
Quick answer: Crysvita is used for Tumor-induced osteomalacia as part of a anti-fgf23 monoclonal antibody treatment regimen. Burosumab is a human monoclonal antibody that binds and inhibits FGF23, restoring renal phosphate reabsorption The specific dosing for Tumor-induced osteomalacia is determined by your prescriber based on individual factors.
Why is Crysvita used for Tumor-induced osteomalacia?
Crysvita belongs to the Anti-FGF23 monoclonal antibody class. Burosumab is a human monoclonal antibody that binds and inhibits FGF23, restoring renal phosphate reabsorption This action makes it useful for treating or managing Tumor-induced osteomalacia in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Crysvita is the right choice for a specific patient depends on the type and severity of Tumor-induced osteomalacia, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Tumor-induced osteomalacia
Common adult dosing range: 0.4-2 mg/kg subcutaneous every 2-4 weeks. The actual dose for Tumor-induced osteomalacia depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Crysvita medicine page.
What to expect
Crysvita treatment for Tumor-induced osteomalacia typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Tumor-induced osteomalacia
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Crysvita is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Anti-FGF23 monoclonal antibody for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Crysvita
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Crysvita full prescribing information · All Anti-FGF23 monoclonal antibody alternatives
Frequently asked questions
How effective is Crysvita for Tumor-induced osteomalacia?
Effectiveness varies by individual response, dose, and severity. Crysvita is one of several treatment options for Tumor-induced osteomalacia, supported by clinical evidence within the anti-fgf23 monoclonal antibody class. Discuss expected response with your prescriber.
How long do I need to take Crysvita for Tumor-induced osteomalacia?
Treatment duration depends on the nature of Tumor-induced osteomalacia — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Crysvita when used for Tumor-induced osteomalacia?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Crysvita for Tumor-induced osteomalacia?
Yes. Multiple medicines and non-drug options exist for Tumor-induced osteomalacia. Alternatives within the anti-fgf23 monoclonal antibody class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.